跳至主要内容
临床试验/NCT00583375
NCT00583375已完成不适用

A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment® Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions

BioMimetic Therapeutics72 个研究点 分布在 2 个国家目标入组 414 人开始时间: 2007年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
414
试验地点
72
主要终点
Subjects Fused at 24 Weeks (as Determined by CT Assessment)

研究概览

简要总结

STUDY OBJECTIVES: Demonstrate equivalent clinical and radiologic outcomes to the "gold standard" (ABG) in a representative clinical model (hindfoot and ankle fusions)

STUDY HYPOTHESIS: Augment® Bone Graft is an equivalent bone grafting substitute to autologous bone graft in applications as shown by non-inferiority analysis

STUDY RATIONALE: Evaluate a fully synthetic growth-factor enhanced bone graft substitute to facilitate fusion in conditions or injuries requiring bone graft in a representative clinical fusion model and thus the opportunity to provide equivalent union rates as ABG without necessitating an additional invasive procedure to harvest the graft

REGULATORY PHASE: Investigational Device Exemption (IDE) for Premarket Approval (PMA) Application as a bone regeneration system, pivotal phase

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1) Bone defect in the hindfoot or ankle requiring fusion using open surgical technique with supplemental bone graft/substitute, requiring one of the following procedures:
  • Ankle joint fusion
  • Subtalar fusion
  • Calcaneocuboid fusion
  • Talonavicular fusion
  • Triple arthrodesis (subtalar, talonavicular and calcaneocuboid joints)
  • Double fusions (talonavicular and calcaneocuboid joints)

排除标准

  • Previous fusion surgery of the proposed fusion site.
  • The patient uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage > 10mg/day).
  • Pregnant or a female intending to become pregnant during this study period.
  • Morbidly obese (BMI > 45 kg/m2)

结局指标

主要结局

Subjects Fused at 24 Weeks (as Determined by CT Assessment)

时间窗: 24 weeks

An independent radiologist examined CT images for all patients' joints and determined whether or not the joint had at least 50% osseous bridging. If a patient demonstrated all joints having at least 50% osseous bridging, this patient was classified as fused.

次要结局

  • Pain on Weight Bearing(24 and 52 Weeks)
  • AOFAS Hindfoot and Ankle Score(24 and 52 weeks)
  • Pain at Fusion Site(24 and 52 weeks)
  • Foot Function Index (FFI)(24 and 52 weeks)
  • SF-12 Physical Component Score(24 and 52 weeks)

研究者

发起方
BioMimetic Therapeutics
申办方类型
Industry
责任方
Sponsor

研究点 (72)

Loading locations...

相似试验